Coronavirus: AstraZeneca and Oxford vaccine on toes of Chinese entrant in AAV space

24 July 2020

Chinese publication Science and Technology Daily has analyzed the progress of the AstraZeneca (LSE: AZN) and University of Oxford coronavirus vaccine alongside a competitor from China.

The article describes these two as the stars on the track of the adenovirus vector vaccines in development for the virus, with Chinese prospect Ad5-nCoV having been the first COVID-19 vaccine around the globe to enter a Phase II clinical trial.

Led by Chen Wei from China Academy of Engineering and researcher at Academy of Military Medical Sciences, Ad5-nCoV is being studied in a trial in which participants aged more than 60 years old are involved, consisting 13% of the 508 total participants.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK